TAYSHA GENE THERAPIES INC (TSHA)

US8776191061 - Common Stock

2.57  -0.01 (-0.39%)

After market: 2.52 -0.05 (-1.95%)

Unregistered users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
2019
(2019-12-31)
Revenue
15.45M2.50M0.000.000.00
Operating Expenses
86.83M128.53M173.27M43.00M1.12M
Research and Development
56.78M91.17M131.94M31.89M990.00K
Selling, General, and Administrative Expenses
30.05M37.36M41.32M11.11M130.00K
Operating Income
-71.37M-126.03M-173.27M-43.00M-1.12M
Interest Income/Expense
-1.43M-3.55M-1.26M20.00KN/A
Other Income/Expense
-36.30M-20.00K0.00-17.03MN/A
Non Recurring Items
-2.46M-36.42MN/AN/AN/A
Income Before Taxes
-111.57M-166.01M-174.52M-60.01M-1.12M
Net Income
-111.57M-166.01M-174.52M-60.01M-1.12M
EBITDA
-70.00M-124.86M-172.78M-42.99MN/A
 
Per Share Data
EPS Diluted Total Ops
-0.96-3.78-4.64-1.74-0.03
Non GAAP EPS
0.13-3.13-4.63N/AN/A
 
Statistics
Profit Margin
-722.06%-6640.40%N/AN/AN/A
Operating Profit Margin
-461.94%-5041.20%N/AN/AN/A

All data in USD

Charts